NasdaqGS:AMRXPharmaceuticals
Amneal Pharmaceuticals (AMRX) Stock Asks If Profit Momentum Can Endure
The market barely flinched at Amneal Pharmaceuticals, with the stock easing about 1% to US$18.32 even after a once again stronger profit story. Q2 headline numbers were clean and pharma focused. Revenue reached US$796 million and adjusted earnings per share landed at US$0.30. Adjusted EBITDA came in at US$206 million. All three sat comfortably within a raised full year outlook.
For a stock that has climbed more than 40% over the past three months, that muted move hints at investors wrestling...